Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR2 | O43603 | 2/20 | 0.54 |
| ▸ | GALR1 | P47211 | 2/20 | 0.54 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.45 |
| ▸ | NPY2R | P49146 | 2/20 | 0.44 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.44 |
| ▸ | GLP1R | P43220 | 8/20 | 0.43 |
| ▸ | GIPR | P48546 | 8/20 | 0.43 |
| ▸ | NPY1R | P25929 | 1/20 | 0.43 |
| ▸ | NPY4R | P50391 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | CALCA | P06881 | 1/20 | 0.43 |
| ▸ | EED | O75530 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13613776 | 1.00 | GALR2 (0.54) | GALR2GALR1KISS1RNPY2RPCSK9 | |
| SCHEMBL13613774 | 0.85 | GALR2 (0.59) | GALR2GALR1GLP1RGIPRCALCA | |
| SCHEMBL29454204 | 0.75 | NPY1R (0.61) | NPY2RGLP1RGIPRNPY1RNPY4R | |
| SCHEMBL30429448 | 0.73 | GALR2 (0.62) | GALR2GALR1KISS1RGLP1RGIPR | |
| SCHEMBL30429667 | 0.73 | NMBR (0.60) | GALR2GALR1KISS1RNPY2RGLP1R | |
| SCHEMBL30429251 | 0.72 | CALCA (0.62) | GALR2GALR1NPY2RGLP1RNPY1R | |
| SCHEMBL29992945 | 0.72 | CALCA (0.59) | GALR2GALR1KISS1RNPY2RNPY1R | |
| Galantide SCHEMBL31332196 | 0.71 | IL23R (0.62) | GALR2GALR1GLP1RGIPR | |
| SCHEMBL31061583 | 0.71 | GALR2 (0.65) | GALR2GALR1GLP1RGIPR | |
| SCHEMBL29973367 | 0.70 | CXCL8 (0.62) | GALR2GALR1GLP1RGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275727-A1 | Peptide turn mimetics | MIMETICA PTY LIMITED (AU) | 2009-11-05 | — | — | US | disclosed |
| US-20090275727-A1 | Peptide turn mimetics | MIMETICA PTY LIMITED (AU) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275727-A1 | Peptide turn mimetics | IAPP, GLP1R, VIP | GALR2 1737/4885GALR1 1017/4885KISS1R 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.